Benefits were consistent across BMI strata and clinical subgroups, with no evidence of effect modification.<h4>Conclusions</h4>In adults with type 2 diabetes and BMI ≤ 30 kg/m2, GLP-1 RAs confer clinically meaningful kidney protection and reduce hospitalization and sepsis, despite neutral cardiovascular effects. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.